Skip to main content
< Back
About
About the conference
Latest updates
Organisers & Partners
App
Press room
Programme 19
Full programme
Tracks
Speakers 19
Keynote speakers
All speakers
Side events 19
Venue 19
About the venue
Location
Rooms
Subscribe
Public health
Sessions
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Cannabis
Professional development and training
Alcohol
Basic science — Public health
Cannabis — Public Health
Harm reduction — Public health
Opiates — Public Health
Public health — New trends
Wednesday, 23 October
10:50
Understanding and improving health and social outcomes
10:50
to
12:20
Networking zone 3 (N3)
Sanna Rönkä
Stimulants — use, harm and interventions
10:50
to
12:20
Networking zone 4 (N4)
Janusz Sieroslawski
Challenges for harm reduction I
10:50
to
12:20
Insights zone 2 (I2)
Meni Malliori
Definition of disorders
10:50
to
12:20
Networking zone 1 (N1)
Viktor Mravčík
Poster guided tour
Progress in alcohol research and responses - EUFAS poster session 1
10:50
to
12:20
Guided poster tours room
Colin Drummond
13:20
Insights on opioid substitution treatment, prison post-release mortality, and cross indicator analysis
Improving the validity of drug-related deaths data for policy making
13:20
to
14:50
Central square 1 (C1)
Isabelle Giraudon
The social effects of addiction futures
Speculative Addictions I
13:20
to
14:50
Futures zone 1 (F1)
Tim Rhodes
Kari Lancaster
A global network of universities as the future of addiction education
13:20
to
14:50
Insights zone 1 (I1)
Kimberly Johnson
Treatment — challenges, determinants and responses
13:20
to
14:50
Networking zone 3 (N3)
Dominique Lopez
Improving delivery of healthcare programmes
13:20
to
14:50
Central square 3 (C3)
Graça Vilar
Risk behaviours in context
13:20
to
14:50
Networking zone 2 (N2)
Anja Busse
15:00
Practical tools developed under the EMCDDA ‘Harm reduction initiative’
Enhancing the role of drug treatment services for HCV elimination among people who inject drugs
15:00
to
16:30
Central square 1 (C1)
Dagmar Hedrich
Matthew Hickman
Lessons learned on European supported drug programming towards an effective, inclusive and balanced drug policies in Central Asia countries
Modernisation, stagnation or roll-back
15:00
to
16:30
Networking zone 4 (N4)
John-Peter Kools
Needs-based planning for substance use treatment systems: The new generation of principles, methods and models
15:00
to
16:30
Insights zone 4 (I4)
Thomas Babor
Drug policy and human rights
15:00
to
16:30
Insights zone 1 (I1)
João Goulão
Epidemiology of hepatitis C among people who use drugs — Data to inform future planning
15:00
to
16:30
Insights zone 3 (I3)
Vana Sypsa
Jack Stone
16:50
Closing the gaps: HIV and Hepatitis continuum of care with a focus on people who inject drugs
16:50
to
18:20
Central square 1 (C1)
Viktor Mravčík
Responding to vulnerability and special needs
16:50
to
18:20
Networking zone 2 (N2)
Kerstin Stenius
18:30
Innovative approaches for assessing or impacting demand for substances
18:30
to
19:30
Central square 1 (C1)
Anne Line Bretteville-Jensen
Smoking and health
18:30
to
19:30
Insights zone 1 (I1)
Robert West
Thursday, 24 October
10:50
The European Mosaic: prescription drug misuse across borders
10:50
to
12:20
Central square 1 (C1)
Richard Dart
Results from ATTUNE
Understanding pathways to stimulant use: a mixed methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe
10:50
to
12:20
Central square 2 (C2)
Marcus-Sebastian Martens
Understanding behaviours, risks and harms
10:50
to
12:20
Networking zone 3 (N3)
Xavier Majó
Providing an international focal point for access to research, training, institutional engagement and credentialing for field-based impact
Building a professional workforce for drug demand reduction
10:50
to
12:20
Insights zone 4 (I4)
Joanna Travis-Roberts
Lancet review series: Using evidence to better respond to drug problems - a call for action
10:50
to
12:20
Main stage
Pam Das
Gender perspectives
10:50
to
12:20
Central square 3 (C3)
Anne Line Bretteville-Jensen
Alcohol perspectives and prevention - EUFAS poster session 2
10:50
to
12:20
Guided poster tours room
Linn Gjersing
13:20
Lessons from the past applied to the future
Post-marketing prescription drug mosaic surveillance
13:20
to
14:50
Main stage
Richard Dart
Focus on prescription drugs I
13:20
to
14:50
Insights zone 3 (I3)
Volker Auwärter
The Reitox network poster session
13:20
to
14:50
Guided poster tours room
Nadine Berndt
15:00
Future addictions EU multi-sector research project game jam
15:00
to
16:30
Futures zone 3 (F3)
Fleur Braddick
Silvia Matrai
Opioid-related deaths and other harms: current and emerging lessons - SSA poster session
15:00
to
16:30
Guided poster tours room
Sarah Welch
16:50
The Swedish ANDT-strategy
How to support the implementation of a comprehensive policy for alcohol, narcotics, doping, and tobacco from a public health perspective
16:50
to
18:20
Insights zone 1 (I1)
Linda Brännström
Methods and measurement of economic cost of substance use
16:50
to
18:20
Central square 3 (C3)
Rosalie Pacula
Striving towards the future elimination of Hep C among people who use drugs
16:50
to
18:20
Futures zone 1 (F1)
Eberhard Schatz
Perrine Roux
18:30
Cannabis labelling and health warnings: use and impacts
18:30
to
19:30
Insights zone 4 (I4)
Hanan Abramovici
Prevention science and measurement of demand reduction quality standards
18:30
to
19:30
Central square 1 (C1)
Nicola Singleton
Friday, 25 October
09:00
Contemporary issues in addictions
09:00
to
10:30
Central square 3 (C3)
Henk Garretsen
10:45
Epidemiology of infectious diseases
10:45
to
12:15
Insights zone 4 (I4)
Thomas Seyler
Opioid-related deaths: learning from epidemiological studies
10:45
to
12:15
Insights zone 3 (I3)
Sarah Welch
Presentations
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Wednesday, 23 October
10:50
Poster
Exposure to alcohol and/or cadmium changes status of bioelements in rat tests
10:50
to
12:20
Guided poster tours room
Mirjana Djukic
Poster
'Drink to forget' – a case report
10:50
to
12:20
Guided poster tours room
Mariana Lázaro
Poster
Screening for alcohol-related cognitive impairments – a case study
10:50
to
12:20
Guided poster tours room
Luisa Gil
Poster
Neuroprotective role of argan oil against alcohol use disorders in adolescent wistar rat
10:50
to
12:20
Guided poster tours room
Hicham El Mostafi
Poster
Cadmium and/or ethanol increase oxidative stress in liver of the exposed rats
10:50
to
12:20
Guided poster tours room
Mirjana Djukic
Poster
Screening and brief interventions for reducing alcohol consumption in a department of firefighters in the central region of Portugal
10:50
to
12:20
Guided poster tours room
Teresa Barroso
Poster
Court proceedings and actions taken by a probation officer in work with people addicted to alcohol.
10:50
to
12:20
Guided poster tours room
Ewelina Silecka-Marek
Poster
Elderly wellbeing and alcohol - a tricky cocktail
10:50
to
12:20
Guided poster tours room
Jakob Emiliussen
11:00
Short communication
Portuguese gender-sensitive harm reduction services: bridging the gap
11:00
to
11:10
Networking zone 3 (N3)
Short communication
Do more people in Europe need treatment for problems related to cocaine use? An analysis of cocaine treatment demand in nine European countries
11:00
to
11:10
Networking zone 4 (N4)
Antoine Jérôme
Oral presentation
Views about the disease and brain disease model of addiction: an international survey of addiction treatment providers in the USA, UK and Australia
11:00
to
11:15
Networking zone 1 (N1)
Anthony Barnett
Oral presentation
Vital signs: the future of the harm reduction model in the National Health Service
11:00
to
11:15
Insights zone 2 (I2)
Marta Borges
11:10
Short communication
A change in the prescribing practice of prebagalin that has had a direct negative effect on drug-induced deaths in Ireland
11:10
to
11:20
Networking zone 3 (N3)
Ena Lynn
Short communication
Psychostimulant induce neuronal plasticity by cytoskeleton remodeling via cdc42 pathway
11:10
to
11:20
Networking zone 4 (N4)
Andrea Lobo
11:15
Oral presentation
Reconsidering cannabis dependence
11:15
to
11:30
Networking zone 1 (N1)
Liz Temple
Oral presentation
Harm reduction and public health: the case of Sweden
11:15
to
11:30
Insights zone 2 (I2)
Lena Eriksson
11:30
Short communication
Performance enhancing drugs. Results from a Belgian survey on PED use among workers
11:30
to
11:40
Networking zone 3 (N3)
Marie-Claire Lambrechts
Oral presentation
Agreement degree with the content of the Substance Addiction Consequences Scale items - The development of a new instrument.
11:30
to
11:45
Networking zone 1 (N1)
Paulo Seabra
Oral presentation
Harm reduction drug policy in Israel: what has and still needs to be accomplished?
11:30
to
11:45
Insights zone 2 (I2)
Hagit Bonny-Noach
11:40
Short communication
Drug and alcohol treatment: how much does it cost in Europe?
11:40
to
11:50
Networking zone 3 (N3)
Claudia Costa Storti
Short communication
Crackland in Brazil: epidemiological monitoring method and results
11:40
to
11:50
Networking zone 4 (N4)
Clarice Madruga
11:45
Oral presentation
Characterising people that demanded drug treatment in Catalonia: a cluster analysis
11:45
to
12:00
Networking zone 1 (N1)
Xavier Majó
Oral presentation
Street Support Project: a harm reduction approach to urban health and integration
11:45
to
12:00
Insights zone 2 (I2)
Roberto Pérez Gayo
11:50
Short communication
Young people's exposure to gambling advertisements: a mixed methods study in Australia.
11:50
to
12:00
Networking zone 3 (N3)
Hannah Pitt
Short communication
'I have no clue why I’m doing this' – a qualitative study on crack cocaine use in Frankfurt, Germany
11:50
to
12:00
Networking zone 4 (N4)
Bernd Werse
12:00
Short communication
Street Work Nursing as an innovative strategy in the care for dually diagnosed individuals: reflections on a pilot study
12:00
to
12:10
Networking zone 3 (N3)
Ilse Goethals
12:10
Short communication
Dissuasion, the effectiveness of the intervention and good practices
12:10
to
12:20
Networking zone 3 (N3)
Américo Gegaloto
13:20
Oral presentation
Epidemiology of drug-related deaths in Europe, and focus in two countries on underestimation and possible corrections of the reported number of deaths
13:20
to
14:50
Central square 1 (C1)
Isabelle Giraudon
Oral presentation
Comparison between drug-related deaths data from special and general mortality registers in Austria. Implications for monitoring and policy making
13:20
to
14:50
Central square 1 (C1)
Judith Anzenberger
Oral presentation
Mortality during and after opioid substitution treatment in Austria 2002 to 2016
13:20
to
14:50
Central square 1 (C1)
Martin Busch
Oral presentation
Prison post-release mortality among drug-users in Lithuania
13:20
to
14:50
Central square 1 (C1)
Lina Jurgelaitiene
Oral presentation
Social learning theory and the globalisation of drug demand reduction education programs
13:20
to
14:50
Insights zone 1 (I1)
Kimberly Johnson
Oral presentation
The systematic mapping survey of academic degree university programs focus on addiction science: up-dated overview
13:20
to
14:50
Insights zone 1 (I1)
Amalie Pavlovská
Oral presentation
Understanding the nature of university-based addiction training programs: results of an international survey
13:20
to
14:50
Insights zone 1 (I1)
Roger Peters
Oral presentation
The role of addiction education programs in the development of national strategies to address drug demand reduction
13:20
to
14:50
Insights zone 1 (I1)
Igor Koutsenok
13:30
Short communication
Treating drug abuse and health issues in the criminal justice system. An empirical research on the linkage of health and criminal justice interventions, France
13:30
to
13:40
Networking zone 3 (N3)
Ivana Obradovic
Short communication
Perceptions on social determinants of opioid dependence recovery
13:30
to
13:40
Networking zone 3 (N3)
Leonor Brito
Oral presentation
Speculating on the social effects of shifting drugs and addictions
13:30
to
13:45
Futures zone 1 (F1)
Helen Keane
Oral presentation
Substance Use Sex Index (SUSI): towards a new behaviour change assessment tool
13:30
to
13:45
Networking zone 2 (N2)
Nadine Ezard
Oral presentation
Balancing welfare and market institutional logics. Procurement regulations for social services, such as addiction treatment, in four Nordic welfare countries
13:30
to
13:45
Central square 3 (C3)
Kerstin Stenius
13:40
Short communication
Reverse transition from injecting to smoking heroin and/or crack cocaine on lower methadone dose: sub-therapeutic dosing or safer drug use?
13:40
to
13:50
Networking zone 3 (N3)
Felicia Heidebrecht
13:45
Oral presentation
How might the past and present shape the future? The case of 'drug control'
13:45
to
14:00
Futures zone 1 (F1)
Virginia Berridge
Oral presentation
Chemsex experiences: pleasures, harms and care
13:45
to
14:00
Networking zone 2 (N2)
Maitena Milhet
Oral presentation
Can liaison and diversion services increase referral to drug and alcohol treatment?
13:45
to
14:00
Central square 3 (C3)
Kate Morley
13:50
Short communication
Benzodiazepine management in primary care: barriers and facilitators
13:50
to
14:00
Networking zone 3 (N3)
Kristien Coteur
14:00
Oral presentation
What kind of addiction treatments, and effects, will biotechnological developments make?
14:00
to
14:15
Futures zone 1 (F1)
Daniel Wolfe
Oral presentation
The counselors’ perspective on the use of methamphetamine in a sexual context among men who have sex with men
14:00
to
14:15
Networking zone 2 (N2)
Valérie Aubut
Oral presentation
Treatment in therapeutic communities: the experience of Lisbon and Tagus Valley Region
14:00
to
14:15
Central square 3 (C3)
Elizabete Pereira
Short communication
Referral of European and third country non-national clients in Belgian drug treatment
14:00
to
14:15
Networking zone 3 (N3)
Eva Blomme
14:10
Short communication
HIV and drug abuse: relationship and treatment challenges
14:10
to
14:20
Networking zone 3 (N3)
Sara Dehanov
14:15
Oral presentation
Faster, higher, stronger? Results from a Belgian survey on PED use among gym-goers
14:15
to
14:30
Networking zone 2 (N2)
Bertrand Fincoeur
Oral presentation
The influence of institutional response on the individual's recovery from drug misuse
14:15
to
14:30
Central square 3 (C3)
Carolina Cunha
Oral presentation
Digital and social media technologies: from drug markets and user networks to detection and surveillance
14:15
to
14:30
Futures zone 1 (F1)
Judith Aldridge
14:20
Short communication
Motivation for treatment predict adherence to treatment in a randomised clinical trial
14:20
to
14:30
Networking zone 3 (N3)
Zhanna Gaulen
14:30
Short communication
Psychiatric assessment of prisoners in opioid-maintenance treatment: emphasis on ADHD
14:30
to
14:40
Networking zone 3 (N3)
Marisa Silbernagl
14:40
Short communication
Perceptions on social determinants of opioid dependence recovery
14:40
to
14:50
Networking zone 3 (N3)
15:00
Oral presentation
The EMCDDA 'Harm reduction initiative' to promote access to hepatitis testing and care
15:00
to
15:15
Central square 1 (C1)
Klaudia Palczak
Oral presentation
The contribution of injecting drug use as a risk factor for Hepatitis C virus transmission globally, regionally, and at country level: a modelling study
15:00
to
15:15
Insights zone 3 (I3)
Adam Trickey
Oral presentation
The current drug situation in the Central Asia
15:00
to
16:30
Networking zone 4 (N4)
Viktor Mravčík
Oral presentation
Results and lessons learned of prevention program to support parents (Closer each other-further from risky behaviours) implemented in Tajikistan and Kazakhstan
15:00
to
16:30
Networking zone 4 (N4)
Janusz Sieroslawski
Boguslawa Bukowska
Oral presentation
The situation of harm reduction and treatment of drug use disorders in public health and in prison system in Central Asia
15:00
to
16:30
Networking zone 4 (N4)
Ingo Michels
Heino Stöver
Oral presentation
Opportunities for supporting modernisation of traditional drug policies in Central Asia
15:00
to
16:30
Networking zone 4 (N4)
John-Peter Kools
15:10
Oral presentation
Measuring unmet demand for alcohol and other treatment: the application of an Australian population-based planning model
15:10
to
15:25
Insights zone 4 (I4)
Alison Ritter
Oral presentation
Drugs policy and Human Rights: Recent trends, developments and challenges at the United Nations
15:10
to
15:25
Insights zone 1 (I1)
Zaved Mahmood
15:15
Oral presentation
A checklist to identify barriers to HCV testing and linkage to care in drug treatment settings – an important element of a diagnostic process
15:15
to
15:25
Central square 1 (C1)
Ruth Zimmermann
Oral presentation
Factors associated with HIV and hepatitis C in the context of routes of drug administration among problem drug users in Latvia, 2018
15:15
to
15:30
Insights zone 3 (I3)
Laura Isajeva
15:25
Oral presentation
The Knowledge questionnaire for staff working with PWID: feedback from a pilot study among 150 health service workers
15:25
to
15:35
Central square 1 (C1)
Nicola Singleton
Oral presentation
The treatment demand indicator in Europe: A common monitoring tool across 30 countries and its value for treatment systems planning
15:25
to
15:40
Insights zone 4 (I4)
Linda Montanari
Oral presentation
Human and sustainable drug policies : the Pompidou Group of the Council of Europe
15:25
to
15:40
Insights zone 1 (I1)
Denis Huber
15:30
Oral presentation
Barriers in the treatment of HCV infection in drug users: inspiring solutions from SCUDO project
15:30
to
15:45
Insights zone 3 (I3)
Felice Alfonso Nava
15:35
Oral presentation
How HCV testing and care can be delivered through drug services: Evidence-base, case studies and 'real life' implementation experiences
15:35
to
15:55
Central square 1 (C1)
Dagmar Hedrich
Eberhard Schatz
15:40
Oral presentation
Development of a needs-based planning model to estimate required capacity of a substance use treatment system: A Canadian model
15:40
to
15:55
Insights zone 4 (I4)
Brian Rush
Oral presentation
What does it mean to adopt a Human Rights approach to drug policy?
15:40
to
15:55
Insights zone 1 (I1)
Damon Barrett
15:45
Oral presentation
HCV care in an opiate substitution therapy program: assessment of infection, liver-related damage, and treatment rates.
15:45
to
16:00
Insights zone 3 (I3)
Roberto Muga
15:55
Oral presentation
Users of alcohol and other drugs residing in the Metropolitan Region of São Paulo: Basis for the planning of a treatment system
15:55
to
16:10
Insights zone 4 (I4)
Daniela Mota
Oral presentation
Promoting human rights in UN drug policy: a civil society perspective
15:55
to
16:10
Insights zone 1 (I1)
Marie Nougier
Oral presentation
Roundtable discussion: identifying barriers and facilitators to HCV testing and access to hepatitis treatment-experience from two European countries
15:55
to
16:30
Central square 1 (C1)
Nadine Berndt
Rita Cardoso Seixas
Karolina Zakrzewska
16:00
Oral presentation
Slamming, drug injection in sexual contexts: increased HIV and HCV exposure for MSM points to a need for intersectional approaches to harm reduction
16:00
to
16:15
Insights zone 3 (I3)
Marie Jauffret-Roustide
16:10
Oral presentation
The evolution of methods to estimate specialist alcohol treatment capacity and access in the United Kingdom
16:10
to
16:25
Insights zone 4 (I4)
Colin Drummond
16:15
Oral presentation
Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: a systematic review and meta-analysis
16:15
to
16:30
Insights zone 3 (I3)
Jason Grebely
17:00
Oral presentation
Socioeconomic status and parental education in vulnerability for substance use disorders
17:00
to
17:15
Networking zone 2 (N2)
Sabrina Molinaro
Oral presentation
National continua of care for HIV and hepatitis C across Europe
17:00
to
17:15
Central square 1 (C1)
Erika Duffell
17:15
Oral presentation
People with lifelong disability and their experiences of pubs and clubs in Australia
17:15
to
17:30
Networking zone 2 (N2)
Hannah Pitt
Oral presentation
Continuum of care for people who inject drugs
17:15
to
17:30
Central square 1 (C1)
Thomas Seyler
17:30
Oral presentation
Hospitalisation of children after prenatal exposure to methamphetamine
17:30
to
17:45
Networking zone 2 (N2)
Svetlana Skurtveit
Oral presentation
Continuum of care in the PWID population in Germany
17:30
to
17:45
Central square 1 (C1)
Ruth Zimmermann
17:45
Oral presentation
Veterans, substance use and trauma-informed care: analysis of veterans’ treatment needs in a multi-state sample of inmates
17:45
to
18:00
Networking zone 2 (N2)
Michele Pich
Oral presentation
Continuum of care in the prison population
17:45
to
18:00
Central square 1 (C1)
Fadi Meroueh
18:00
Oral presentation
The association of traumatic experiences, perceived discrimination and affective symptoms with substance use among Russian and Kurdish migrants in Finland: a population-based study
18:00
to
18:15
Networking zone 2 (N2)
Essi Salama
Oral presentation
Continuum of care among the prison and PWID population in Luxembourg
18:00
to
18:15
Central square 1 (C1)
Nadine Berndt
Rita Cardoso Seixas
18:30
Oral presentation
Healthy recovery: results and reflections from a stepped wedge randomised controlled trial of a healthy lifestyle intervention within substance dependence treatment
18:30
to
18:45
Insights zone 1 (I1)
Peter Kelly
Oral presentation
USODROGAS.PT: Portugal's drug use: a web based survey
18:30
to
18:45
Central square 1 (C1)
André Tadeu
18:45
Oral presentation
Clearing the smoke: vaping cannabis among adolescents. Recent trends and implications
18:45
to
19:00
Insights zone 1 (I1)
Alexandra Kritikos
Oral presentation
Partnering with persons in long-term recovery from substance use disorder: experiences from a collaborative research project
18:45
to
19:00
Central square 1 (C1)
Henning Pettersen
19:00
Oral presentation
Tobacco harm reduction: key themes
19:00
to
19:15
Insights zone 1 (I1)
Harry Shapiro
Oral presentation
Validation of the Routine Opioid Outcome Monitoring (ROOM) screening tool in patients prescribed opioids for chronic pain
19:00
to
19:15
Central square 1 (C1)
Suzanne Nielsen
19:15
Oral presentation
A systematic review and network meta-analysis of the safety and effectiveness of smoking cessation medicines and electronic cigarettes
19:15
to
19:30
Insights zone 1 (I1)
Kyla Thomas
Oral presentation
Adoption of publication procedures to improve research integrity by alcohol and other drug journals
19:15
to
19:30
Central square 1 (C1)
Dennis Gorman
Thursday, 24 October
10:50
Oral presentation
The Mosaic approach to post-marketing surveillance
10:50
to
11:00
Central square 1 (C1)
Richard Dart
Oral presentation
Addressing the Future: An International Focal Point for Drug Demand Reduction
10:50
to
12:20
Insights zone 4 (I4)
Joanna Travis-Roberts
Oral presentation
Building an international credentialing system for drug demand reduction professionals
10:50
to
12:20
Insights zone 4 (I4)
Becky Vaughn
Oral presentation
Establishing and Supporting a consortium of universities to provide academic provision of drug demand reduction
10:50
to
12:20
Insights zone 4 (I4)
Kimberly Johnson
Oral presentation
A European training initiative to encourage the growth of an international prevention workforce
10:50
to
12:20
Insights zone 4 (I4)
Peer van der Kreeft
Oral presentation
Introduction to the European ATTUNE study: overview of aim, objectives and design of the project
10:50
to
12:20
Central square 2 (C2)
Uwe Verthein
Oral presentation
Understanding different pathways of ATS use over time: results and conclusions from in-depth qualitative interviews in five European countries
10:50
to
12:20
Central square 2 (C2)
Amy O’Donnell
Oral presentation
Motives for and consequences from ATS use: findings from a multinational survey of ATS users and non-users
10:50
to
12:20
Central square 2 (C2)
Nienke Liebregts
Oral presentation
Associations between personality traits, sensation seeking, self-efficacy, resilience and patterns of ATS use
10:50
to
12:20
Central square 2 (C2)
Magdalena Rowicka
Marcus-Sebastian Martens
Oral presentation
Impact of critical life events on ATS use trajectories
10:50
to
12:20
Central square 2 (C2)
Benjamin Petruzelka
Poster
Alcohol addiction as a social problem in Ukraine: history of research
10:50
to
12:20
Guided poster tours room
Larysa Klymanska
Poster
The alcohol consumption in the modern Ukraine: tendences and perspecties.
10:50
to
12:20
Guided poster tours room
Larysa Klymanska
Poster
Alcohol and drugs in contemporary school pupils on the verge of adolescence: the Polish experience
10:50
to
12:20
Guided poster tours room
Katarzyna Pawelek
Poster
The role of alcohol in fatal fires in Ireland
10:50
to
12:20
Guided poster tours room
Anne Doyle
Poster
Do parents want to change alcohol legislations to protect their children?
10:50
to
12:20
Guided poster tours room
Marta Zin-Sedek
Poster
Social and context determinants of drinking during working time – Portuguese GPS findings 2017
10:50
to
12:20
Guided poster tours room
Cláudia Urbano
Poster
Sub-groups of tobacco and alcohol co-use trajectories from ages 21 to 32: the Amsterdam growth and health longitudinal study
10:50
to
12:20
Guided poster tours room
Sterling McPherson
Poster
Effects of an alcohol prevention program at sport stadiums: a 2-year follow-up study using pseudopatrons and breath alcohol concentration levels
10:50
to
12:20
Guided poster tours room
Tobias Elgan
Poster
Implementing and evaluating alcohol and drug prevention methods at youth health clinics
10:50
to
12:20
Guided poster tours room
Pia Kvillemo
Oral presentation
Global patterns of opioid use and dependence: population harms, interventions, and future action
10:50
to
12:20
Main stage
Louisa Degenhardt
Oral presentation
Public health implications of legalising the production and sale of cannabis for medicinal and recreational use
10:50
to
12:20
Main stage
Wayne Hall
Oral presentation
Responding to growing global stimulant use: challenges and opportunities
10:50
to
12:20
Main stage
Michael Farrell
Oral presentation
The new psychoactive substance phenomenon: current and future challenges for drug surveillance, control, and public health responses
10:50
to
12:20
Main stage
Amy Peacock
Oral presentation
Discussion and the future
10:50
to
12:20
Main stage
Louisa Degenhardt
Pam Das
Paul Griffiths
Wayne Hall
Michael Farrell
Amy Peacock
Poster
Accessing alcohol drinking influence in workplace – What is the panorama and current innovations in Portugal?
10:50
to
12:20
Guided poster tours room
Duarte Vital Brito
11:00
Short communication
Neuropsychological functioning, psychopathology, and parenting behaviours in the context of substance use disorders: which are the implications for treatment?
11:00
to
11:10
Networking zone 3 (N3)
Alessio Porreca
Oral presentation
Prescription Drug Misuse in the U.K.
11:00
to
11:15
Central square 1 (C1)
David Wood
Oral presentation
Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study
11:00
to
11:15
Central square 3 (C3)
Judit Tirado-Muñoz
11:10
Short communication
Childhood adversity within adolescent friendship groups: Implications for subsequent substance use disorders
11:10
to
11:20
Networking zone 3 (N3)
Lauren Bishop
11:15
Oral presentation
Prescription drug misuse in Spain
11:15
to
11:30
Central square 1 (C1)
Francina Fonseca
Oral presentation
A gendered approach to women’s lived experiences of gambling harm: preliminary findings
11:15
to
11:30
Central square 3 (C3)
Simone McCarthy
11:20
Short communication
Cause-specific hospitalisation and death in a cohort of people who use heroin and crack cocaine in London, England: the importance of non-communicable diseases, skin infections, head injuries and dental caries
11:20
to
11:40
Networking zone 3 (N3)
Dan Lewer
11:30
Short communication
Yearning to be better than good –Lithuanian students of medicine use of cognitive enhancers among
11:30
to
11:40
Networking zone 3 (N3)
Aiste Lengvenyte
Oral presentation
Prescription drug misuse in Germany
11:30
to
11:45
Central square 1 (C1)
John Schwarz
Oral presentation
How can partners influence the gambling habits of their gambler spouse?
11:30
to
11:45
Central square 3 (C3)
Melissa Cote
11:40
Short communication
New issues regarding drug-related deaths: combined suicide
11:40
to
11:50
Networking zone 3 (N3)
Mateja Jandl
11:45
Oral presentation
Prescription drug misuse in France and Italy
11:45
to
12:00
Central square 1 (C1)
Janetta Iwanicki
Oral presentation
Methamphetamine use during pregnancy and weak evidence of adverse neonatal outcomes
11:45
to
12:00
Central square 3 (C3)
Roman Gabrhelik
11:50
Short communication
Women and HIV in prison setting: data from the Italian ROSE network
11:50
to
12:00
Networking zone 3 (N3)
12:00
Short communication
Non-national clients in Belgian drug treatment: different profile characteristics compared to Belgian clients
12:00
to
12:10
Networking zone 3 (N3)
Charlotte De Kock
13:20
Poster
Trends on the Dutch drug market identified by DIMS in 2018
13:20
to
14:50
Guided poster tours room
Laura Smit-Rigter
Poster
Gendered sources of drug supply for recreational drug users in the European Web Survey on Drugs
13:20
to
14:50
Guided poster tours room
Michael Vuolo
Poster
Trends in primary substance mentioned by patients entering treatment for illicit substance use in Belgium between 2012 and 2018
13:20
to
14:50
Guided poster tours room
Antoine Jérôme
Poster
Criminal reactions and reduction of crime and drug use in drug-using offenders
13:20
to
14:50
Guided poster tours room
Olga Souza Cruz
Poster
Fatal traffic accidents in connection to driving under the influence of psychoactive substances
13:20
to
14:50
Guided poster tours room
Ada Hocevar Grom
Poster
HIV infection in drug users in harm reduction structures
13:20
to
14:50
Guided poster tours room
Isabel Ponte
Poster
Drug-related deaths and mortality in Europe
13:20
to
14:50
Guided poster tours room
Federica Mathis
Poster
Demand for drug treatment in Europe: the Treatment Demand indicator (TDI)
13:20
to
14:50
Guided poster tours room
Linda Montanari
Poster
Non-medical prescription drug use among Estonian adults
13:20
to
14:50
Guided poster tours room
Sigrid Vorobjov
Poster
Monitoring drug-related infectious diseases in Europe
13:20
to
14:50
Guided poster tours room
Thomas Seyler
Poster
Estimating the number of people who inject drugs (PWID) in Europe
13:20
to
14:50
Guided poster tours room
Thomas Seyler
13:30
Oral presentation
Principles and strategies for post-marketing surveillance of prescription drugs
13:30
to
13:45
Main stage
Richard Dart
Oral presentation
The off-prescription use of modafinil: an online survey of perceived risks and benefits
13:30
to
13:45
Insights zone 3 (I3)
Rachel Teodorini
13:45
Oral presentation
Better methods: Novel methods and analyses to better understand prescription drug misuse
13:45
to
14:00
Main stage
Janetta Iwanicki
Oral presentation
Prospective cohort to assess the impact of removing non-prescription codeine in Australia
13:45
to
14:00
Insights zone 3 (I3)
Jacqui McCoy
14:00
Oral presentation
Prescription opioid misuse in Europe: Past, present, and future
14:00
to
14:15
Main stage
Marta Torrens Melich
Oral presentation
Characteristics and problematic opioid use in people prescribed opioids for CNCP over four years: a prospective cohort study
14:00
to
14:15
Insights zone 3 (I3)
Gabrielle Campbell
14:15
Oral presentation
The future of prescription drug abuse beyond opioids: A U.K. perspective
14:15
to
14:30
Main stage
David Wood
Oral presentation
A qualitative study of gabapentin use and misuse: perspectives of substance abuse treatment professionals
14:15
to
14:30
Insights zone 3 (I3)
Mance Buttram
15:00
Poster
Dosing of naloxone in opioid overdose outside of hospital. Observational data 2014 -18 in Oslo, Norway
15:00
to
16:30
Guided poster tours room
Ida Tylleskär
Poster
Increasing trend and differential patterns of opioids prescribing by patient characteristics in primary care in Belgium: a registry-based study
15:00
to
16:30
Guided poster tours room
Catharina Matheï
Poster
Patterns in analgesic opioids use in Germany and France: improved pain management and risks of misuse
15:00
to
16:30
Guided poster tours room
Jessica Neicun
Poster
Barriers to establishing take-home naloxone programmes
15:00
to
16:30
Guided poster tours room
Sibella Hare Breidahl
Poster
Patient characteristics and expected needs: an opioid substitution programme findings
15:00
to
16:30
Guided poster tours room
Catarina Oliveira
Poster
Benzodiazepine use among patients in opioid substituttion treatment: a cross sectional study
15:00
to
16:30
Guided poster tours room
Catarina Oliveira
Poster
Hospitalisation of children after prenatal exposure to Methadone and Buprenorphine: national registry study from Czechia
15:00
to
16:30
Guided poster tours room
Blanka Nechanská
Poster
Uncovering trajectories of satisfaction with injectable opioid agonist treatment for severe opioid use disorder
15:00
to
16:30
Guided poster tours room
Kirsten Marchand
Poster
Predicting pain intensity following discontinuation of long-term opioid therapy among patients with and without substance use disorders
15:00
to
16:30
Guided poster tours room
Crystal Smith
Poster
Addressing the opioid crisis: engagement in multidisciplinary care
15:00
to
16:30
Guided poster tours room
Tianna Magel
Poster
Comparing rates and characteristics of harms across different pharmaceutical opioids: an examination of Australian ambulance attendances 2013-2018
15:00
to
16:30
Guided poster tours room
Tina Lam
Future addictions EU multi-sector research project game jam
15:00
to
16:30
Futures zone 3 (F3)
Fleur Braddick
16:50
Oral presentation
A community-based peer-driven program to reach people who inject drugs, monitor risk behaviours and 'test and treat' for infectious diseases in Athens, Greece: ARISTOTLE HCV-HIV
16:50
to
17:05
Futures zone 1 (F1)
Vana Sypsa
Oral presentation
Modeling economical costs of alcohol consumption in Germany: the GECO-ALC1 project
16:50
to
17:05
Central square 3 (C3)
Jakob Manthey
Oral presentation
Monitoring systems
16:50
to
18:20
Insights zone 1 (I1)
Mimmi Erikkson Tinghög
Oral presentation
National and regional coordination and initiative to achieve the objectives of the strategy
16:50
to
18:20
Insights zone 1 (I1)
Linda Brännström
Oral presentation
Assessing results of the ANDT strategy
16:50
to
18:20
Insights zone 1 (I1)
Jenny Hansson
17:05
Oral presentation
Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study
17:05
to
17:20
Futures zone 1 (F1)
Jason Grebely
Oral presentation
Estimating substance use costs and harms in Canada
17:05
to
17:20
Central square 3 (C3)
Matthew Young
17:20
Oral presentation
Low HCV-RNA prevalence and low anti HCV incidence in a large national sample of PWID in opioid substitution treatment in Germany: a prospective cohort study
17:20
to
17:35
Futures zone 1 (F1)
Bernd Schulte
Oral presentation
Morbi-mortality consequences of misuse of psychoactive prescription drugs in Portugal: a retrospective observational study - the MisuMedPT project
17:20
to
17:35
Central square 3 (C3)
Ana Araújo
17:35
Oral presentation
Monitoring the elimination of hepatitis C and B among people who inject drugs in Europe
17:35
to
17:50
Futures zone 1 (F1)
Thomas Seyler
17:50
Oral presentation
'Towards eliminating viral hepatitis': A critical examination of the performativity of hepatitis C elimination goals and targets
17:50
to
18:05
Futures zone 1 (F1)
Kari Lancaster
18:05
Oral presentation
Evidencing viral elimination futures: modelling, targets and the end of Hep C
18:05
to
18:20
Futures zone 1 (F1)
Tim Rhodes
18:40
Oral presentation
Use of an adapted version of the community readiness assessment to examine the current state of alcohol prevention in communities in Spain and Portugal
18:40
to
18:55
Central square 1 (C1)
Claudia Pischke
Oral presentation
Cannabis labelling and consumer understanding of THC levels and serving sizes.
18:40
to
18:55
Insights zone 4 (I4)
Samantha Goodman
18:55
Oral presentation
Building systems to promote prevention science: challenges and strategies
18:55
to
19:10
Central square 1 (C1)
Peer van der Kreeft
Oral presentation
The impact of cannabis health warning labels on risk awareness and behaviour
18:55
to
19:10
Insights zone 4 (I4)
Adam Winstock
19:10
Oral presentation
Minimum quality standards in drug demand reduction - from policy consensus to assessment and implementation
19:10
to
19:25
Central square 1 (C1)
Matej Košir
Oral presentation
The efficacy of health warnings and package branding on perceptions of cannabis products among youth and young adults.
19:10
to
19:25
Insights zone 4 (I4)
Cesar Leos-Toro
Friday, 25 October
09:15
Oral presentation
Assessing the impact of laws controlling the online availability of 25I-NBOMe, AH-7921, MDPV and MXE – outcomes of a semi-automated e-shop monitoring. Drugs: education, prevention and policy
09:15
to
09:30
Central square 3 (C3)
Vendula Belackova
09:30
Oral presentation
Some constitutional issues regarding control of new psychoactive substances
09:30
to
09:45
Central square 3 (C3)
Krzysztof Krajewski
09:45
Oral presentation
Making the National Strategy on Addiction work for practitioners in addiction aid: how Swiss authorities and civil society bridge theory and practice
09:45
to
10:00
Central square 3 (C3)
Mirjam Weber
10:00
Oral presentation
Leveraging citizen science and the power of civil society networks in a trans European mobile application
10:00
to
10:15
Central square 3 (C3)
Florian Scheibein
10:55
Oral presentation
Overdose deaths in people prescribed opioids for chronic non-cancer pain: Systematic review and meta-analysis
10:55
to
11:10
Insights zone 3 (I3)
Sarah Larney
Oral presentation
Infectious diseases among people who inject drugs in France: the importance of acting on risk environment in an evolving crisis
10:55
to
11:10
Insights zone 4 (I4)
Marie Jauffret-Roustide
11:10
Oral presentation
Hidden aspects of the opioid crisis: what factors are driving ageing trends among those using opioid drugs?
11:10
to
11:25
Insights zone 3 (I3)
Anne Marie Carew
Oral presentation
Pakistan’s heterogeneous HIV epidemic in people who inject drugs: identifying key contributing factors
11:10
to
11:25
Insights zone 4 (I4)
Aaron Lim
11:25
Oral presentation
Comparing rates and characteristics of harms across different pharmaceutical opioids: an examination of Australian ambulance attendances 2013-2018.
11:25
to
11:40
Insights zone 3 (I3)
Tina Lam
Oral presentation
Modelling HIV transmission amongst high-risk groups to determine the extent that HIV transmission is driven by key populations and risk behaviours in Tijuana, Mexico
11:25
to
11:40
Insights zone 4 (I4)
Hannah Fraser
11:40
Oral presentation
Causes of death among patients in opioid maintenance treatment in Norway
11:40
to
11:55
Insights zone 3 (I3)
Anne Berit Bech
Oral presentation
Characteristics of polydrug use and associations with HIV risk behaviours among people who inject drugs in two cities in Europe
11:40
to
11:55
Insights zone 4 (I4)
Isabel Tavitian-Exley
11:55
Oral presentation
Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs
11:55
to
12:10
Insights zone 3 (I3)
Kirsten Trayner
Oral presentation
Modelling the impact of prevention and treatment interventions on HIV and Hepatitis C virus transmission among PWID in Nairobi
11:55
to
12:10
Insights zone 4 (I4)
Jack Stone
Hannah Fraser